Dunhill Medical Trust
The Dunhill Medical Trust (DMT) grantees whose proposals were submitted from 2008 onwards are required to submit an electronic copy of the final manuscript of their research papers to PubMed Central (PMC) or UK PubMed Central (UKPMC). DMT will provide a contribution towards the valid costs of open access fees levied by publishers who support the open access model, and require payment to allow manuscripts to become available in UKPMC within six months of the publisher’s official date of final publication.
The funding provided will be in the form of a one-off sum that will be added to the grant awarded by DMT and the amount will be on a sliding scale dependent on the size of the grant, i.e.:
Grants up to £50,000 - £1,000 Grants from £50,000 to £100,000 - £2,000 Grants over £100,000 - £3,000 Note: Applicants are not required to apply for this funding. It will be automatically added to all research project and programme grants awarded by DMT. Grant holders will however be expected to account in their final report for their use of the funding provided and will be required to provide evidence that publications arising from the work funded are available on open access site(s). (see the DMT website).
Elsevier’s policy will allow authors who publish in Elsevier journals to comply with these requirements. This policy is intended to support the needs of Elsevier authors, editors and society publishing partners, and to protect the quality and integrity of the peer-review process.
DMT-funded authors publishing in Elsevier journals can comply with the DMT policy by paying a fee to the journal to help offset the cost of peer review and other publishing costs. The fee has initially been set at $3,000 per article for all Elsevier journals except those published by Cell Press, which have a $5,000 per article fee, and The Lancet, which will have a fee of £400 per page. The difference in fees for The Lancet and Cell Press reflects higher associated costs.
Upon final publication, Elsevier will send to UKPMC, on the author’s behalf, the final document used to generate the published journal article that appears on ScienceDirect. This document reflects all author-agreed changes that arise from the peer-review, copy-editing and proofing processes. Elsevier will authorize its public posting on UKPMC, and mirror sites, immediately. UKPMC and mirror sites will also link directly to the final published journal article, which will continue to reside only on Elsevier’s websites and which Elsevier will make freely available to both non-subscribers and subscribers. Subject to certain conditions, documents published under this sponsorship model may be redistributed and reused.
There is no change to Elsevier’s author posting policy that allows authors to voluntarily post revised personal versions of manuscripts (those that reflect changes made in the peer review) on their own websites and the sites of their institutions, provided a link to the journal is included. Posting directly to UKPMC or other sites outside an author’s institution continues to be prohibited, as does any further republishing or redistribution of Elsevier copyright-protected content and society copyright-protected content published by Elsevier. This new policy enables DMT-funded authors to comply with the DMT policy without having to violate their publishing agreements with Elsevier.
This policy is consistent with Elsevier’s long-standing record of adapting to meet authors’ changing needs, preserving the quality and integrity of the peer-review process, and providing value throughout the publishing cycle. It is another example of Elsevier’s ongoing engagement with scientific and academic communities to explore ways to deliver demonstrable and sustainable benefits for the research communities we serve.